Our creative, effective, and entrepreneurial approach to drug development reduces the drug development cycle time and yields success


MediVector’s strong development program is transitioning Favipiravir from being considered simply a treatment for a single indication to being hailed as a potential “one drug, many bugs” solution.


MediVector cut the development time for an anti-inflammatory drug for the treatment of asthma from 4.5 years to 1.5 years, saving significant time and cost.


MediVector helped achieve FDA approval for a therapeutic monoclonal antibody for treatment of B-cell chronic lymphocytic leukemia.